NVCT
Nuvectis Pharma Inc
NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY
$23.00
+4.64% today
Updated 2026-09-22
Market cap
$713.93M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.32
Dividend yield
—
52W range
$6 – $29
Volume
0.2M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →250 stocks currently score above 75
Price targets
Analyst target
$35.40
+53.91%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-4.53M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $149000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-18.79M | $-22.26M | $-19.00M | $-26.44M | $-7.02M |
| EPS | — | — | — | — | $-1.32 |
| Free cash flow | $-13.56M | $-15.95M | $-12.25M | $-16.01M | $-4.53M |
| Profit margin | -12,608.72% | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-03 | CARSON, MICHAEL J. | Buy | 30,000 | — |
| 2026-06-30 | MOSSERI, MARLIO CHARLES | Buy | 50,000 | $18.32 |
| 2026-06-30 | BENTSUR, RON | Buy | 12,500 | $20.00 |
Peer comparison
Smart narrative
Nuvectis Pharma Inc trades at $23.00. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.
Frequently asked questions
What is Nuvectis Pharma Inc's stock price?
Nuvectis Pharma Inc (NVCT) trades at $23.00.
Is Nuvectis Pharma Inc overvalued?
Nuvectis Pharma Inc carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Nuvectis Pharma Inc (NVCT)?
The 12-month analyst consensus target is $35.40, about 53.9% above the current $23.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-306.61%
Beta-0.26
50D MA$21.11
200D MA$12.52
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.2M
Performance
1 week-8.30%
1 month-6.62%
3 months+59.19%
YTD+191.39%
1 year+250.88%
3 years—
5 years—